We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Curious about Elanco Animal Health (ELAN) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Read MoreHide Full Article
In its upcoming report, Elanco Animal Health Incorporated (ELAN - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.20 per share, reflecting a decline of 33.3% compared to the same period last year. Revenues are forecasted to be $1.19 billion, representing a year-over-year increase of 0.1%.
Over the last 30 days, there has been an upward revision of 1.5% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
That said, let's delve into the average estimates of some Elanco Animal Health metrics that Wall Street analysts commonly model and monitor.
Analysts predict that the 'Revenue- Total Pet Health' will reach $601.90 million. The estimate points to a change of +4% from the year-ago quarter.
Analysts expect 'Revenue- Total Contract Manufacturing' to come in at $10.89 million. The estimate indicates a change of -1.1% from the prior-year quarter.
Based on the collective assessment of analysts, 'Revenue- Total Farm Animal' should arrive at $573.69 million. The estimate points to a change of -3.4% from the year-ago quarter.
Elanco Animal Health shares have witnessed a change of -3.7% in the past month, in contrast to the Zacks S&P 500 composite's +0.5% move. With a Zacks Rank #3 (Hold), ELAN is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Curious about Elanco Animal Health (ELAN) Q2 Performance? Explore Wall Street Estimates for Key Metrics
In its upcoming report, Elanco Animal Health Incorporated (ELAN - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.20 per share, reflecting a decline of 33.3% compared to the same period last year. Revenues are forecasted to be $1.19 billion, representing a year-over-year increase of 0.1%.
Over the last 30 days, there has been an upward revision of 1.5% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
That said, let's delve into the average estimates of some Elanco Animal Health metrics that Wall Street analysts commonly model and monitor.
Analysts predict that the 'Revenue- Total Pet Health' will reach $601.90 million. The estimate points to a change of +4% from the year-ago quarter.
Analysts expect 'Revenue- Total Contract Manufacturing' to come in at $10.89 million. The estimate indicates a change of -1.1% from the prior-year quarter.
Based on the collective assessment of analysts, 'Revenue- Total Farm Animal' should arrive at $573.69 million. The estimate points to a change of -3.4% from the year-ago quarter.
View all Key Company Metrics for Elanco Animal Health here>>>Elanco Animal Health shares have witnessed a change of -3.7% in the past month, in contrast to the Zacks S&P 500 composite's +0.5% move. With a Zacks Rank #3 (Hold), ELAN is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .